The primary goal of this project is to use differences in the human response to a single vaccine antigen to determine factors that are critical to the ability of an individual to make a protective response to the vaccine. The vaccine antigen used in these studies is the major surface antigen of Hepatitis B virus, HBsAg. Using a broad range of tools, including genome-wide transcriptional profiling, multiparameter flow cytometry and detailed functional phenotyping of antigen-specific T cell subset, we will determine which components of the innate and adaptive response to vaccine correlate best with the seroprotective response to vaccination. The major part of this project will be a systems biology study of the same antigen, HBsAg, with two different adjuvants. Alum and the Toll-like receptor-9 agonist, CpG-ODN. Clinical trials have shown CpG-ODN to be a much more effective vaccine, especially in subjects that respond poorly to vaccination due age or disease. We propose to compare transcriptional and cellular responses to these two adjuvants in older healthy adults and later in patients with end-stage renal disease of HIV infection. This study presents a unique opportunity to study in humans the mechanisms of action of the most widely used adjuvant, alum and one of the most promising modern adjuvant candidates, CpG-ODN, in a study in which the adjuvants are the only significant variable. These studies will constitute an important advance in our understanding of the actions of adjuvants and will hopefully identify the primary reasons for unresponsiveness to vaccination in older adults and in specific disease states.
Many adults respond poorly to vaccination because of old age or disease. As a result, many of the people most in need of vaccination are not effectively protected. New vaccine adjuvants offer promise for improving results in these difficult to immunize groups, but the way they work is not understood. The goal of this project is to provide a clear understanding of how vaccine adjuvants work in poorly responding individuals and to suggest new strategies to develop improved vaccines for these groups.
|Hogstad, Brandon; Berres, Marie-Luise; Chakraborty, Rikhia et al. (2018) RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 215:319-336|
|Cepika, Alma-Martina; Banchereau, Romain; Segura, Elodie et al. (2017) A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis. J Exp Med 214:3449-3466|
|Athale, Shruti; Banchereau, Romain; Thompson-Snipes, LuAnn et al. (2017) Influenza vaccines differentially regulate the interferon response in human dendritic cell subsets. Sci Transl Med 9:|
|Banchereau, Romain; Cepika, Alma-Martina; Banchereau, Jacques et al. (2017) Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics. Annu Rev Immunol 35:337-370|
|Silvin, Aymeric; Yu, Chun I; Lahaye, Xavier et al. (2017) Constitutive resistance to viral infection in human CD141+ dendritic cells. Sci Immunol 2:|
|Schotsaert, Michael; García-Sastre, Adolfo (2017) Inactivated influenza virus vaccines: the future of TIV and QIV. Curr Opin Virol 23:102-106|
|HIPC-CHI Signatures Project Team; HIPC-I Consortium (2017) Multicohort analysis reveals baseline transcriptional predictors of influenza vaccination responses. Sci Immunol 2:|
|Bentebibel, Salah-Eddine; Khurana, Surender; Schmitt, Nathalie et al. (2016) ICOS(+)PD-1(+)CXCR3(+) T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination. Sci Rep 6:26494|
|Heinonen, Santtu; Jartti, Tuomas; Garcia, Carla et al. (2016) Rhinovirus Detection in Symptomatic and Asymptomatic Children: Value of Host Transcriptome Analysis. Am J Respir Crit Care Med 193:772-82|
|Sandoval, Carmen; Barrera, Aldo; Ferrés, Marcela et al. (2016) Infection in Health Personnel with High and Low Levels of Exposure in a Hospital Setting during the H1N1 2009 Influenza A Pandemic. PLoS One 11:e0147271|
Showing the most recent 10 out of 60 publications